AOD-9604 Reconstitution Calculator

No. AOD-9604 is not FDA-approved for obesity, fat loss, or joint repair, and clinical development for obesity was terminated after randomized, double-blind, placebo-controlled trials failed to show a statistically significant dose-dependent weight-loss effect versus placebo despite a favorable short-term safety profile. It is a modified fragment of human growth hormone covering residues 177-191 with an added tyrosine for stability.

Best human answer: probably not to a clinically meaningful degree. Human trials summarized in the safety literature included more than 900 participants and found good short-term tolerability but no convincing dose-dependent superiority to placebo for weight loss, which is why development stopped. (RCT/review)

Preclinical answer: yes in rodents. In obese mice and rats, AOD-9604 increased fat oxidation, increased lipolysis markers, reduced body-weight gain, and did so without the hyperglycemia or reduced insulin secretion seen with intact growth hormone. (animal/mechanistic)

AOD-9604 was designed to isolate the lipolytic region of growth hormone while avoiding classic growth-hormone-receptor effects. It does not meaningfully bind the GH receptor, does not stimulate cell proliferation through that receptor, and in human safety studies did not change IGF-1 or insulin sensitivity; proposed fat-loss signaling appears related to beta-adrenergic pathways rather than direct GH receptor agonism. (mechanistic/animal/human safety)

Human comparative efficacy data are lacking. Oral activity is biologically plausible because obese Zucker rats given 500 mcg/kg/day orally for 19 days had >50% lower weight gain than controls, but that is animal data only and did not translate into clear human obesity efficacy. (animal)

For real-world use, most current protocols use oral capsules or troches at 250-500 mcg once daily, usually fasted in the morning, while older gray-market protocols also used subcutaneous microdoses in the same range (community protocol). There is no published human evidence showing one route outperforms another for weight loss.

No evidence-based human dosing regimen can be recommended for fat loss because efficacy was not established in RCTs. Common nonclinical practice uses 250-500 mcg once daily, sometimes split 250 mcg twice daily, for 8-12 weeks (community protocol). Weight-based dosing is not established in humans; the main published oral animal dose was 500 mcg/kg/day in rats, which should not be directly extrapolated to people.

Studied human use was short term, and that is the only interval with any direct safety signal. The available human data support short-term tolerability, but there is no good evidence for long-term efficacy or long-term safety, especially because chronic beta-adrenergic pathway stimulation is a theoretical concern. (human safety/review)

Practical use, if attempted, is usually limited to 8-12 weeks followed by reassessment rather than continuous use (practitioner consensus). If there is no measurable change in body weight, waist circumference, or appetite within 6-8 weeks, continuing longer has weak rationale given the negative human obesity trials.

Probably yes on the specific issues of IGF-1 stimulation and diabetogenicity, but that does not mean it is effective. In animal models, AOD-9604 reduced weight gain and increased fat oxidation without the hyperglycemia and reduced insulin secretion seen with intact human growth hormone, and it did not bind the GH receptor or trigger GH-receptor-mediated proliferation. Human safety studies also found no change in IGF-1 or insulin sensitivity. (animal/human safety)

The tradeoff is efficacy: growth hormone has stronger biological effects, while AOD-9604 appears pharmacologically narrower and clinically weaker for body-composition change.

Only animal evidence supports this. In a rabbit osteoarthritis model, weekly intra-articular 0.25 mg AOD9604 improved gross and histopathologic cartilage scores versus saline, and combining 0.25 mg AOD9604 with 6 mg hyaluronic acid performed better than either alone. There is no human joint trial supporting oral AOD-9604, and no human evidence that systemic use repairs cartilage. (animal)

Because of that gap, using AOD-9604 for knee pain or osteoarthritis is speculative. The best interpretation is “promising preclinical signal, no human validation.”

Short-term human studies found AOD-9604 generally well tolerated, with no signal for IGF-1 elevation or impaired insulin sensitivity. (human safety) Published long-term safety data are sparse, and the review literature notes a theoretical risk from prolonged beta-adrenergic signaling, including dysautonomia-type symptoms such as palpitations or autonomic intolerance. (review/mechanistic)

Practical adverse effects reported in community use are usually mild and nonspecific: nausea, headache, restlessness, and appetite changes (community protocol). If symptoms suggest sympathetic overstimulation, stopping is the usual response (practitioner consensus).

No if they are subject to anti-doping rules. AOD-9604 is treated as a prohibited peptide in sports-drug testing literature, is detectable in urine at very low concentrations, and stable metabolites have been characterized to extend the detection window. (analytical/doping)

GLP-1 receptor agonists are far stronger and better supported clinically. AOD-9604 failed to produce reliable placebo-separated weight loss in human trials, while the review literature explicitly points to approved anti-obesity alternatives such as GLP-1 receptor agonists and phentermine for meaningful weight reduction. (RCT/review)

If the goal is measurable fat loss rather than experimentation with a GH fragment, the evidence base favors approved obesity medications over AOD-9604.